Skip to content
BiologicalX

Comparison

Melatonin vs Sermorelin

Side-by-side of Melatonin and Sermorelin. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.

Effects at a glance

Melatonin

  • Shortens sleep onset latency by ~7 to 12 minutes at physiological 0.3 to 1 mg doses
  • Advances circadian phase when taken 30 to 60 minutes before target bedtime, useful for jet lag and shift work
  • Does not meaningfully increase total sleep time in healthy adults without circadian misalignment
  • Endogenous nighttime production is not suppressed by short-term exogenous supplementation
  • Higher doses (3 to 10 mg) raise plasma levels above physiological range and often increase morning grogginess
  • Effective for delayed sleep-wake phase disorder and reducing jet-lag severity in eastward travel

Sermorelin

  • Synthetic 29-amino-acid GHRH fragment; FDA approved 1997 for pediatric GH deficiency as Geref
  • Voluntarily discontinued by Serono in 2008 for commercial reasons; not safety-related
  • Compounded by 503A/503B pharmacies for off-label adult anti-aging and body-composition use
  • Produces physiologic pulsatile GH release; ~10 to 20 minute plasma half-life
  • Standard anti-aging clinic protocol: 200 to 500 mcg subcutaneously pre-bed, often with ipamorelin
  • Banned by WADA under S2 (peptide hormones, growth factors)

Side-by-side

Attribute Melatonin Sermorelin
Category supplement peptide
Also known as N-acetyl-5-methoxytryptamine Sermorelin acetate, GRF 1-29, Geref, GHRH (1-29) NH2
Half-life (hr) 0.75 0.25
Typical dose (mg) 0.5 0.3
Dosing frequency daily, 30 to 60 minutes before target sleep time 1-2x daily
Routes oral, sublingual subcutaneous
Onset (hr) 0.5 0.25
Peak (hr) 1 0.5
Molecular weight 232.28 3357.88
Molecular formula C13H16N2O2 C149H246N44O42S
Mechanism Agonist at MT1 and MT2 receptors in the suprachiasmatic nucleus, signaling biological night and promoting sleep-onset gating plus circadian phase shifts. Synthetic 29-amino-acid GHRH fragment that binds the GHRH receptor on pituitary somatotrophs to stimulate endogenous pulsatile GH synthesis and release while preserving the GH-IGF-1 negative feedback loop.
Legal status OTC in US; prescription in UK, EU, Japan FDA approved 1997 (Geref, pediatric GHD); voluntarily discontinued by Serono 2008; compounded by 503A/503B pharmacies for off-label adult use; banned by WADA
WADA status allowed banned
DEA / Rx OTC supplement in US; Rx in UK, EU, Japan, Australia Rx only via compounding (no controlled-substance schedule)
Pregnancy Insufficient data; not routinely recommended Category C (historical labeling); not recommended in pregnancy
CAS 73-31-4 86168-78-7
PubChem CID 896 16129617
Wikidata Q179243 Q416620

Safety profile

Melatonin

Common side effects

  • vivid dreams
  • morning grogginess (higher doses)
  • headache
  • dizziness

Contraindications

  • autoimmune disease (theoretical)
  • concurrent anticoagulant therapy without monitoring

Interactions

  • fluvoxamine: CYP1A2 inhibition raises melatonin levels substantially(major)
  • warfarin: possible increased bleeding risk(moderate)
  • benzodiazepines and alcohol: additive sedation(moderate)
  • antihypertensives: may alter blood pressure response(minor)

Sermorelin

Common side effects

  • injection-site pain or irritation
  • transient flushing
  • headache
  • vivid dreams (pre-bed dosing)

Contraindications

  • pregnancy
  • active malignancy
  • history of pituitary tumor
  • diabetic retinopathy (theoretical)
  • untreated hypothyroidism

Interactions

  • ipamorelin: synergistic GH release via parallel GHRH and ghrelin pathways; standard anti-aging clinic pairing(minor)
  • CJC-1295: pharmacologically redundant (both GHRH-pathway); typically not stacked(minor)
  • insulin: sustained GH can blunt insulin sensitivity over weeks(moderate)
  • corticosteroids: blunt GH response; reduce expected efficacy(moderate)
  • levothyroxine (untreated hypothyroidism): untreated hypothyroidism blunts GH response; correct thyroid first(moderate)

Which Should You Take?

Melatonin comes out ahead for most readers on the criteria we weight: 2 catalogued goals, OTC, oral dosing, with a Tier-A outcome catalogued. Sermorelin is the right call when one of the conditionals below applies.

  • If your priority is sleep onset or sleep quality, pick Melatonin.
  • If your priority is circadian regulation, pick Melatonin.
  • If your priority is growth-hormone axis, pick Sermorelin.
  • If your priority is healthspan extension, pick Sermorelin.

Edge case: If you want to avoid FDA approved 1997 (Geref, pediatric GHD); voluntarily discontinued by Serono 2008; compounded by 503A/503B pharmacies for off-label adult use; banned by WADA, Melatonin is the more accessible choice.

Default choice: Melatonin. Wider use case, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Sermorelin only if your priority sits squarely in the goals it owns above.

This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.

Common questions

What is the difference between Melatonin and Sermorelin?

Melatonin and Sermorelin differ in category (supplement vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.

Which has a longer half-life, Melatonin or Sermorelin?

Melatonin half-life is 0.75 hours; Sermorelin half-life is 0.25 hours.

Can you stack Melatonin with Sermorelin?

Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.

Go deeper